Lv3
334 积分 2026-03-10 加入
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
1天前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
1天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
1天前
已完结
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
2天前
已完结
EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery
6天前
已完结
Development of Proteasome Inhibitors for Cancer Therapy
29天前
已关闭
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
29天前
已完结
Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells
30天前
已完结
Antibody-Drug Conjugates in Oncology: Why Potency Is No Longer the Limiting Factor
30天前
已关闭
SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
1个月前
已完结
皖公网安备34019202002308
